-
公开(公告)号：US20240082419A1
公开(公告)日：2024-03-14
申请号：US18469292
申请日：2023-09-18
发明人： Gang QIN , Meijun XIONG , Mingyu HU
CPC分类号： A61K47/6889 , A61K47/549 , A61K47/65 , A61K47/68031 , A61K47/68033 , A61K47/68035 , A61K47/68037 , A61K47/6805 , A61K47/6809 , A61K47/6811 , A61P35/00
摘要： The present disclosure further relates to a linker-payload compound including an oligosaccharide group, especially a disaccharide group, where the oligosaccharide group is linked to the remainder of the compound by an amide bond. The present disclosure further relates to an antibody-drug conjugate (ADC) containing the linker-payload compound, where the glycan chain in an antibody is remodeled with the oligosaccharide moiety in the linker-payload compound. The present disclosure further relates to preparation methods and use of the above-mentioned substances.
-
公开(公告)号：US11819531B2
公开(公告)日：2023-11-21
申请号：US15099234
申请日：2016-04-14
申请人： Kodiak Sciences Inc.
IPC分类号： A61K49/00 , A61K47/58 , A61K47/54 , A61K38/00 , A61K47/68 , C12N9/96 , A61K38/18 , A61K38/46 , A61K39/395 , C07K16/00 , C08F8/32 , C08F230/02 , C12N9/16 , C08F230/08
CPC分类号： A61K38/00 , A61K38/1816 , A61K38/465 , A61K39/395 , A61K47/544 , A61K47/58 , A61K47/6805 , A61K47/6811 , A61K49/0002 , A61K49/0043 , A61K49/0054 , C07K16/00 , C08F8/32 , C08F230/02 , C12N9/16 , C12N9/96 , C12Y301/03001 , C07K2317/21 , C07K2317/55 , C08F230/085 , C08F2438/01 , C08F230/02 , C08F230/085
摘要： The present invention provides random copolymers containing zwitterions and one or more functional agents, and methods of preparing such random copolymers.
-
公开(公告)号：US20170266311A1
公开(公告)日：2017-09-21
申请号：US15457574
申请日：2017-03-13
发明人： Donald A. BERGSTROM , Natalya D. BODYAK , Timothy B. LOWINGER , Peter U. PARK , Laura L. POLING , Aleksandr V. YURKOVETSKIY
CPC分类号： C07K16/3023 , A61K47/6805 , A61K47/6811 , A61K47/6851 , A61K47/6857 , A61K47/6869 , A61K47/6883 , C07K16/3069 , C07K16/32 , C07K2317/21 , C07K2317/24 , C07K2317/565
摘要： This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.
-
4.发明授权Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions 有权药物或其他药物与具有C末端延伸的工程抗体的位点特异性连接公开(公告)号：US08865875B2
公开(公告)日：2014-10-21
申请号：US12674503
申请日：2008-08-19
申请人： Jie Liu , David King
发明人： Jie Liu , David King
CPC分类号： C07K16/2875 , A61K47/6803 , A61K47/6805 , A61K47/6819 , A61K47/6869 , A61K47/6889 , C07K16/3069 , C07K2317/21
摘要： The present invention provides antibodies (e.g., IgG antibodies) having C-terminal cysteine-containing extensions that facilitate antibody conjugation to a partner molecule (e.g. a drug, toxin, marker molecule, protein, radioisotope, or other therapeutic agent). Methods of making, screening and selecting the antibodies of the invention are provided.
摘要翻译： 本发明提供了具有C末端半胱氨酸延伸的抗体（例如，IgG抗体），其有助于抗体与配偶体分子（例如药物，毒素，标记分子，蛋白质，放射性同位素或其它治疗剂）缀合。 提供制备，筛选和选择本发明抗体的方法。
-
5.发明授权Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof 有权抗IGF-1R和/或抗胰岛素/ IGF-I杂合受体抗体及其用途公开(公告)号：US08808999B2
公开(公告)日：2014-08-19
申请号：US13352599
申请日：2012-01-18
申请人： Liliane Goetsch , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
CPC分类号： A61K47/6805 , C07K2317/732
摘要： The present invention relates to methods of identifying IGF-IR modulators and hybrid-R modulators comprising contacting IGF-IR with a humanized anti-IGF-IR antibody and contacting hybrid-R with a humanized anti-hybrid-R antibody, respectively.
摘要翻译： 本发明涉及鉴定IGF-1R调节剂和杂合-R调节剂的方法，其包括将IGF-1R与人源化抗IGF-1R抗体接触并分别使杂交-R与人源化抗混合-R抗体接触。
-
公开(公告)号：US07914784B2
公开(公告)日：2011-03-29
申请号：US11783513
申请日：2007-04-10
申请人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-François Haeuw , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-François Haeuw , Alain Beck
IPC分类号： A61K39/395 , A61K39/00 , C12P21/08 , C07K16/18 , C07K16/28
CPC分类号： A61K47/6805 , C07K2317/732 , Y10S425/81
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
摘要翻译： 本发明涉及能够特异性结合人类胰岛素样生长因子I受体IGF-1R和/或能够特异性抑制所述IGF-1R受体的酪氨酸激酶活性的新型抗体，特别是鼠，嵌合体的单克隆抗体， 人源化，以及编码这些抗体的氨基酸和核酸序列。 本发明同样包括使用这些抗体作为用于预防和/或治疗过度表达IGF-1R的癌症或与所述受体的过度表达相关的任何病理学以及用于诊断与所述受体相关的疾病的过程或试剂盒 IGF-1R受体的过度表达。 本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂的组合的产品和/或组合物及其用于预防和/或治疗某些癌症的用途。
-
公开(公告)号：US20080286198A1
公开(公告)日：2008-11-20
申请号：US11783513
申请日：2007-04-10
申请人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-Francois Haeuw , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-Francois Haeuw , Alain Beck
IPC分类号： A61K51/10 , C07H21/04 , C12N15/63 , C12N5/06 , A01K67/027 , C12P21/00 , G01N33/53 , C07K16/28 , A61K39/395 , A61P35/00 , A61K39/44
CPC分类号： A61K47/6805 , C07K2317/732 , Y10S425/81
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
-
公开(公告)号：US20080193445A1
公开(公告)日：2008-08-14
申请号：US11801080
申请日：2007-05-08
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： A61K39/3955 , A61K47/6803 , A61K47/6805 , A61K47/6807 , A61K47/6809 , A61K47/6819 , A61K47/6847 , A61K47/6913 , A61K2039/507 , C07K16/22 , C07K2317/732
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
摘要翻译： 本发明涉及能够特异性结合人类胰岛素样生长因子I受体IGF-1R和/或能够特异性抑制所述IGF-1R受体的酪氨酸激酶活性的新型抗体，特别是鼠，嵌合体的单克隆抗体， 人源化，以及编码这些抗体的氨基酸和核酸序列。 本发明同样包括使用这些抗体作为用于预防和/或治疗过度表达IGF-1R的癌症或与所述受体的过度表达相关的任何病理学以及用于诊断与所述受体相关的疾病的过程或试剂盒 IGF-1R受体的过度表达。 本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂组合的产品和/或组合物及其用于预防和/或治疗某些癌症的用途。
-
公开(公告)号：US07029895B2
公开(公告)日：2006-04-18
申请号：US10426776
申请日：2003-04-30
申请人： Maria A. Glucksmann , Mark J. Williamson , Fong-Ying Tsai , Laura A. Rudolph-Owen , Rosanna Kapeller-Libermann , Rachel E. Meyers , Lillian Wei-Ming Chiang , John Joseph Hunter
发明人： Maria A. Glucksmann , Mark J. Williamson , Fong-Ying Tsai , Laura A. Rudolph-Owen , Rosanna Kapeller-Libermann , Rachel E. Meyers , Lillian Wei-Ming Chiang , John Joseph Hunter
CPC分类号： C12N9/1288 , A01K2217/05 , A61K38/00 , A61K47/6805 , A61K47/6809 , A61K47/6821 , A61K48/00 , A61K2039/505 , C07K14/4747 , C07K2319/00 , C12N9/14 , C12N9/16 , C12N9/6472 , G01N33/5011 , G01N33/57407 , G01N33/57484 , G01N2500/10
摘要： The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC 17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
摘要翻译： 本发明提供分离的核酸分子和蛋白质，命名为27411,23413,22438,23553,25278,26212，NARC SC1，NARC 10A，NARC 1，NARC 12，NARC 13，NARC 17，NARC 25，NARC 3，NARC 4， NARC 7，NARC 8，NARC 11，NARC 14A，NARC 15，NARC 16，NARC 19，NARC 20，NARC 26，NARC 27，NARC 28，NARC 30，NARC 5，NARC 6，NARC 9，NARC 10C，NARC 8B ，NARC 9，NARC2A，NARC 16B，NARC 1C，NARC 1A，NARC 25，86604和32222核酸分子和蛋白质。 本发明还提供了反义核酸分子，含有所述核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，其中所述基因已导入或破坏的非人类转基因动物，融合蛋白，抗原肽和抗体 到蛋白质。 还提供了利用本发明组合物的诊断和治疗方法。
-
公开(公告)号：US20050084906A1
公开(公告)日：2005-04-21
申请号：US10735916
申请日：2003-12-16
申请人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-Francois Haeuw , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-Francois Haeuw , Alain Beck
CPC分类号： A61K47/6805 , C07K2317/732 , Y10S425/81
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
摘要翻译： 本发明涉及能够特异性结合人类胰岛素样生长因子I受体IGF-1R和/或能够特异性抑制所述IGF-1R受体的酪氨酸激酶活性的新型抗体，特别是鼠，嵌合体的单克隆抗体， 人源化，以及编码这些抗体的氨基酸和核酸序列。 本发明同样包括使用这些抗体作为用于预防和/或治疗过度表达IGF-1R的癌症或与所述受体的过度表达相关的任何病理学以及用于诊断与所述受体相关的疾病的过程或试剂盒 IGF-1R受体的过度表达。 本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂的组合的产品和/或组合物及其用于预防和/或治疗某些癌症的用途。
-
-
-
-
-
-
-
-
-
搜索结果
60 条记录 (耗时 0.077 秒)
